ANGUO WU^1,#, JIAO YAN^2,3,#, TING SU^2,4, CHI FENG¹, XIN LONG^5,6, YIRU PAN¹, RUPEI YE², TIAN XIA², HANAN LONG², JIANMING WU^1,*, XIULI XIAO^2,*

Oncology Research, Vol.32, No.7, pp. 1197-1207, 2024, DOI:10.32604/or.2024.046139

Abstract Breast cancer, a predominant global health issue, requires ongoing exploration of new therapeutic strategies. Palbociclib (PAL), a well-known cyclin-dependent kinase (CDK) inhibitor, plays a critical role in breast cancer treatment. While its efficacy is recognized, the interplay between PAL and cellular autophagy, particularly in the context of the RAF/MEK/ERK signaling pathway, remains insufficiently explored. This study investigates PAL’s inhibitory effects on breast cancer using both in vitro (MCF7 and MDA-MB-468 cells) and in vivo (tumor-bearing nude mice) models. Aimed at elucidating the impact of PAL on autophagic processes and exploring the potential of combining it with trametinib… More > Graphic Abstract

ISIDORA PETROVIC¹, MILENA MILIVOJEVIC¹, ANA ARSENIJEVIC², ANDRIJANA LAZIC¹, NATASA KOVACEVIC GRUJICIC¹, MARIJA SCHWIRTLICH¹, JELENA POPOVIC³, MILENA STEVANOVIC^1,4,5,*

BIOCELL, Vol.45, No.5, pp. 1355-1367, 2021, DOI:10.32604/biocell.2021.015817

Abstract Genetic and molecular heterogeneity, together with intrinsic and acquired resistance to therapy, represent the major obstacles to the successful treatment of different types of breast carcinoma. Increasing evidence demonstrates that SOX transcription factors in breast carcinomas could act both as oncogenes and tumor suppressors and have been associated with tumor stage and grade, poor prognosis, and therapy resistance. Both SOX2 and SOX18 overexpression has been correlated with poor prognosis in breast carcinomas, and these genes are recognized as potential antitumor targets. Our aim was to evaluate the effect of retinoic acid (RA), a well-known cyto-differentiating agent,… More >